Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ashley Mischke

Plano, TX Physician Assistant

NPI 1518512904 CMS profile 11285368

6124 W Parker Rd Ste 234, Plano, TX 75093

Open in the dashboard

General payments

$1,919

82 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashley Mischke of Plano, TX is reported in the CMS Open Payments database as having received $1,919 across 82 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $31 1
2024 General $242 6
2023 General $960 27
2022 General $409 26
2021 General $277 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashley Mischke
  • Texas median
  • Middle half of Texas
  • National median

In program year 2025, general payments to Ashley Mischke were reported at $31. Among 86,592 Texas profiles paid that year, the median was $188 and the middle half received between $55 and $669.

Show as a table
Year Ashley Mischke Texas median Middle half National median
2019 $0 $191 $56–$744 $163
2020 $0 $125 $38–$452 $114
2021 $277 $150 $43–$543 $132
2022 $409 $169 $50–$606 $149
2023 $960 $183 $53–$639 $160
2024 $242 $188 $55–$666 $164
2025 $31 $188 $55–$669 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Ferring Pharmaceuticals Inc. $694 47 payments
  2. Axonics Modulation Technologies, Inc. $435 10 payments
  3. Sumitomo Pharma America, Inc. $226 9 payments
  4. EMD Serono, Inc. $182 1 payment
  5. AbbVie, Inc. $164 3 payments
  6. Astellas Pharma US Inc $114 6 payments
  7. Boston Scientific Corporation $24 1 payment
  8. Pfizer Inc. $19 1 payment
  9. Duchesnay USA Incorporated $17 1 payment
  10. Novo Nordisk Inc $15 1 payment
  11. Other $30 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,919 82 payments
Products named General payments · program years 2021–2025
  1. MENOPUR $651 45 payments
  2. Axonics $415 9 payments
  3. GEMTESA $226 9 payments
  4. BOTOX Urology $122 1 payment
  5. MYRBETRIQ $114 6 payments
  6. BOTOX Botox Therapeutic $31 1 payment
  7. INVOCELL $21 1 payment
  8. GANIRELIX ACETATE $21 1 payment
  9. Bulkamid $20 1 payment
  10. PREMARIN $19 1 payment
  11. Other $123 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

240

Median for Physician Assistant: 241

Drug cost

$104,401

Median for Physician Assistant: $4,110

Branded share of claims

49.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 45 $46,264
Gemtesa Vibegron Brand 26 $36,118
Mirabegron Er Mirabegron Brand 21 $16,233
Estradiol Generic 40 $2,437
Methenamine Hippurate Generic 24 $1,880
Trospium Chloride Generic 24 $930
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 26 $355
Metronidazole Generic 12 $95
Cephalexin Generic 22 $89

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $122
$122 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $59
$59 26 —
MYRBETRIQ
  • Astellas Pharma US Inc $37
$37 45 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

82 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record